Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
1.
Arch Acad Emerg Med ; 10(1): e75, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-36426173

RESUMO

Cyanosis is typically a sign of a potentially life-threatening condition in the emergency department and requires immediate workup and treatment. This case report highlights the diagnostic reasoning and clinical approach to cocaine- and volatile nitrite-induced methemoglobinemia (MHG). MHG is a rare, life-threatening cause of cyanosis. The diagnosis must be suspected in the emergency department in the presence of hypoxia and cyanosis disproportionate to cardiopulmonary repercussions and refractory to oxygen supplementation. Acquired causes are more prevalent than genetics, and recreational drugs should be highly suspected. Despite the rarity of this situation, cyanosis precipitants and the specificities of each hemoglobinopathy are reviewed in this article.

2.
Clinics (Sao Paulo) ; 73: e216, 2018 05 17.
Artigo em Inglês | MEDLINE | ID: mdl-29791520

RESUMO

OBJECTIVES: Chronic thromboembolic pulmonary hypertension is one of the most prevalent forms of pulmonary hypertension and is a major complication of acute pulmonary embolism. One mainstay of chronic thromboembolic pulmonary hypertension treatment is lifelong anticoagulation. The recent advent of direct oral anticoagulants for acute pulmonary embolism treatment has provided a viable and effective alternative for treating this condition. However, little is known about the efficacy of this new class of drugs for treating chronic thromboembolic pulmonary hypertension. We aimed to evaluate the safety and efficacy of direct oral anticoagulants in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: A cohort of chronic thromboembolic pulmonary hypertension patients who initiated treatment with direct oral anticoagulants between June 2015 and November 2016 were enrolled in this study. RESULTS: Sixteen patients used rivaroxaban, three used dabigatran and one used apixaban for a mean follow-up of 20.9 months. The mean age was 51 years, and eighteen patients were classified as functional class II/III. Eight patients underwent a pulmonary endarterectomy and exhibited clinical, hemodynamic and functional improvement and currently continue to use direct oral anticoagulants. No episode of venous thromboembolism recurrence was identified during the follow-up period, but there was one episode of major bleeding after a traumatic fall. CONCLUSIONS: Although direct oral anticoagulants appear to be a safe and effective alternative for treating chronic thromboembolic pulmonary hypertension, larger studies are needed to support their routine use.


Assuntos
Antitrombinas/administração & dosagem , Dabigatrana/administração & dosagem , Hipertensão Pulmonar/tratamento farmacológico , Embolia Pulmonar/tratamento farmacológico , Pirazóis/administração & dosagem , Piridonas/administração & dosagem , Administração Oral , Adulto , Idoso , Doença Crônica , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Resultado do Tratamento , Vitamina K/antagonistas & inibidores
4.
Clinics ; 73: e216, 2018. tab
Artigo em Inglês | LILACS | ID: biblio-890747

RESUMO

OBJECTIVES: Chronic thromboembolic pulmonary hypertension is one of the most prevalent forms of pulmonary hypertension and is a major complication of acute pulmonary embolism. One mainstay of chronic thromboembolic pulmonary hypertension treatment is lifelong anticoagulation. The recent advent of direct oral anticoagulants for acute pulmonary embolism treatment has provided a viable and effective alternative for treating this condition. However, little is known about the efficacy of this new class of drugs for treating chronic thromboembolic pulmonary hypertension. We aimed to evaluate the safety and efficacy of direct oral anticoagulants in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: A cohort of chronic thromboembolic pulmonary hypertension patients who initiated treatment with direct oral anticoagulants between June 2015 and November 2016 were enrolled in this study. RESULTS: Sixteen patients used rivaroxaban, three used dabigatran and one used apixaban for a mean follow-up of 20.9 months. The mean age was 51 years, and eighteen patients were classified as functional class II/III. Eight patients underwent a pulmonary endarterectomy and exhibited clinical, hemodynamic and functional improvement and currently continue to use direct oral anticoagulants. No episode of venous thromboembolism recurrence was identified during the follow-up period, but there was one episode of major bleeding after a traumatic fall. CONCLUSIONS: Although direct oral anticoagulants appear to be a safe and effective alternative for treating chronic thromboembolic pulmonary hypertension, larger studies are needed to support their routine use.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Embolia Pulmonar/tratamento farmacológico , Pirazóis/administração & dosagem , Piridonas/administração & dosagem , Antitrombinas/administração & dosagem , Dabigatrana/administração & dosagem , Hipertensão Pulmonar/tratamento farmacológico , Vitamina K/antagonistas & inibidores , Doença Crônica , Administração Oral , Reprodutibilidade dos Testes , Resultado do Tratamento
5.
J Bras Pneumol ; 42(2): 146-54, 2016 Apr.
Artigo em Inglês, Português | MEDLINE | ID: mdl-27167437

RESUMO

Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.


Assuntos
Anticoagulantes/uso terapêutico , Tromboembolia Venosa/tratamento farmacológico , Dabigatrana/uso terapêutico , Humanos , Pirazóis/uso terapêutico , Piridinas/uso terapêutico , Piridonas/uso terapêutico , Rivaroxabana/uso terapêutico , Tiazóis/uso terapêutico , Fatores de Tempo , Varfarina/uso terapêutico
6.
J. bras. pneumol ; 42(2): 146-154, Mar.-Apr. 2016. tab, graf
Artigo em Inglês | LILACS | ID: lil-780891

RESUMO

Worldwide, venous thromboembolism (VTE) is among the leading causes of death from cardiovascular disease, surpassed only by acute myocardial infarction and stroke. The spectrum of VTE presentations ranges, by degree of severity, from deep vein thrombosis to acute pulmonary thromboembolism. Treatment is based on full anticoagulation of the patients. For many decades, it has been known that anticoagulation directly affects the mortality associated with VTE. Until the beginning of this century, anticoagulant therapy was based on the use of unfractionated or low-molecular-weight heparin and vitamin K antagonists, warfarin in particular. Over the past decades, new classes of anticoagulants have been developed, such as factor Xa inhibitors and direct thrombin inhibitors, which significantly changed the therapeutic arsenal against VTE, due to their efficacy and safety when compared with the conventional treatment. The focus of this review was on evaluating the role of these new anticoagulants in this clinical context.


O tromboembolismo venoso (TEV) está entre as principais causas de morte por doenças cardiovasculares no mundo, atrás apenas do infarto agudo do miocárdio e do acidente vascular cerebral. O TEV possui espectro de apresentação que vai desde a trombose venosa profunda até o tromboembolismo pulmonar agudo, de acordo com gravidade crescente de acometimento, sendo seu tratamento baseado na anticoagulação plena dos pacientes. Há muitas décadas, sabe-se que a anticoagulação interfere diretamente na mortalidade associada ao TEV. Até o início deste século a terapia anticoagulante se baseava no uso de heparina, em suas formas não fracionada ou de baixo peso molecular, e de antagonistas da vitamina K, principalmente a varfarina. Ao longo das últimas décadas, foram desenvolvidos novas classes de medicamentos anticoagulantes, inibidores do fator Xa e inibidores diretos da trombina, que mudaram significativamente o arsenal terapêutico do TEV, em função de suas características de eficácia e segurança em relação ao tratamento convencional, sendo o foco principal de esta revisão avaliar seu papel neste contexto clínico.


Assuntos
Humanos , Anticoagulantes/uso terapêutico , Tromboembolia Venosa/tratamento farmacológico , Dabigatrana/uso terapêutico , Pirazóis/uso terapêutico , Piridinas/uso terapêutico , Piridonas/uso terapêutico , Rivaroxabana/uso terapêutico , Tiazóis/uso terapêutico , Fatores de Tempo , Varfarina/uso terapêutico
7.
BMC Pulm Med ; 15: 118, 2015 10 12.
Artigo em Inglês | MEDLINE | ID: mdl-26459359

RESUMO

BACKGROUND: Schistosomiasis associated pulmonary arterial hypertension (Sch-PAH) might represent the most prevalent form of PAH worldwide. In Sch-PAH, the presence of aneurismal dilation of the pulmonary artery has been described, although it is still a matter of debate whether on average the pulmonary artery is more enlarged in Sc-PAH than IPAH. METHODS: We retrospectively evaluated patients with IPAH (n = 25) and Sch-PAH (n = 22) who underwent computed tomography pulmonary angiogram and right heart catheterization. RESULTS: Sch-PAH patients were older and presented less severe hemodynamic profiles. Main pulmonary artery diameter (MPAD) was greater in Sch-PAH than IPAH (4.5 ± 1.8 vs 3.7 ± 1.1 cm, p = 0.018). For the same level of mean pulmonary artery pressure, the MPAD in Sch-PAH was 0.89 cm larger than in IPAH (Covariance model p = 0.02). CONCLUSION: This study demonstrated that pulmonary artery enlargement is more pronounced in Sch-PAH than IPAH, independently of mean pulmonary artery pressure level, suggesting that this is more likely a feature of Sch-PAH.


Assuntos
Aneurisma/diagnóstico por imagem , Hipertensão Pulmonar Primária Familiar/diagnóstico por imagem , Artéria Pulmonar/diagnóstico por imagem , Esquistossomose/complicações , Adulto , Angiografia , Feminino , Humanos , Hipertensão Pulmonar/diagnóstico por imagem , Hipertensão Pulmonar/etiologia , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão , Estudos Retrospectivos
10.
Pulmäo RJ ; 24(2): 3-8, 2015. tab
Artigo em Português | LILACS | ID: lil-778783

RESUMO

A hipertensão pulmonar apresentou desenvolvimento bastante significativo nas últimas duas décadas, devido ao maior conhecimento fisiopatológico de suas mais diversas formas. Espelhando esse desenvolvimento, houve evolução da definição assim como do sistema de classificação da hipertensão pulmonar que divide os pacientes em 5 grupos distintos: hipertensão arterial pulmonar (HAP); Hipertensão pulmonar causada por doenças do coração esquerdo; Hipertensão pulmonar causada por doença pulmonar e/ou hipóxia; Hipertensão pulmonar tromboembólica crônica e Hipertensão pulmonar com mecanismos multifatoriais ou não esclarecidos. A classificação adequada dos pacientes é a base para a instituição terapêutica apropriada, particularmente considerando que a evidência atual que sustenta o uso das medicações disponíveis principalmente na doença arterial pulmonar. Sua adoção reforça a necessidade de avaliação diagnóstica abrangente em todos os casos de hipertensão pulmonar...


Pulmonary hypertension showed significant development in the last two decades due to higher pathophysiological knowledge of its various forms. Mirroring these developments, there was evolution of the definition as well as pulmonary hypertension classification system that divides patients into five groups: pulmonary arterial hypertension (PAH); Pulmonary hypertension caused by left heart diseases; Pulmonary hypertension caused by pulmonary disease and / or hypoxia; Chronic thromboembolic pulmonary hypertension and pulmonary hypertension with multifactorial mechanisms or unclear. The appropriate classification of patients is the basis for appropriate therapeutic institution particularly since the current evidence supporting the use of drugs available mainly in the lung artery disease. Its adoption reinforces the need for comprehensive diagnostic evaluation in all cases of pulmonary hypertension...


Assuntos
Humanos , Masculino , Feminino , Hipertensão Pulmonar/classificação , Hipertensão Pulmonar/etiologia , Circulação Pulmonar
11.
J. bras. pneumol ; 40(6): 609-616, Nov-Dec/2014. tab, graf
Artigo em Inglês | LILACS | ID: lil-732562

RESUMO

OBJECTIVE: To evaluate the role of right heart catheterization in the diagnosis of pulmonary arterial hypertension (PAH). METHODS: We evaluated clinical, functional, and hemodynamic data from all patients who underwent right heart catheterization because of diagnostic suspicion of PAH-in the absence of severe left ventricular dysfunction (LVD), significant changes in pulmonary function tests, and ventilation/perfusion lung scintigraphy findings consistent with chronic pulmonary thromboembolism-between 2008 and 2013 at our facility. RESULTS: During the study period, 384 patients underwent diagnostic cardiac catheterization at our facility. Pulmonary hypertension (PH) was confirmed in 302 patients (78.6%). The mean age of those patients was 48.7 years. The patients without PH showed better hemodynamic profiles and lower levels of B-type natriuretic peptide. Nevertheless, 13.8% of the patients without PH were categorized as New York Heart Association functional class III or IV. Of the 218 patients who met the inclusion criteria, 40 (18.3%) and 178 (81.7%) were diagnosed with PH associated with LVD (PH-LVD) and with PAH, respectively. The patients in the HP-LVD group were significantly older than were those in the PAH group (p < 0.0001). CONCLUSIONS: The proportional difference between the PAH and PH-LVD groups was quite significant, considering the absence of echocardiographic signs suggestive of severe LVD during the pre-catheterization investigation. Our results highlight the fundamental role of cardiac catheterization in the diagnosis of PAH, especially in older patients, in whom the prevalence of LVD that has gone undiagnosed by non-invasive tests is particularly relevant. .


OBJETIVO: Avaliar o papel do cateterismo de câmaras cardíacas direitas no diagnóstico de hipertensão arterial pulmonar (HAP). MÉTODOS: Entre 2008 e 2013, foram avaliadas as características clínicas, funcionais e hemodinâmicas de todos os pacientes que realizaram cateterismo cardíaco direito por suspeita de HAP em nosso laboratório, depois de afastada a presença de disfunção ventricular esquerda (DVE) grave, de alterações significativas nos testes de função pulmonar ou de resultados de cintilografia pulmonar de inalação/perfusão compatíveis com tromboembolismo pulmonar crônico. RESULTADOS: Durante o período de estudo, 384 pacientes foram submetidos a cateterismo cardíaco diagnóstico. A hipertensão pulmonar (HP) foi confirmada em 302 pacientes (78,6%). A média de idade desses pacientes foi de 48,7 anos. Os pacientes sem HP apresentaram melhor perfil hemodinâmico e menores níveis de peptídio natriurético do tipo B que aqueles diagnosticados com HP. No entanto, 13,8% dos pacientes sem HP apresentavam-se em classe funcional III/IV do New York Heart Association. Dos 218 pacientes que cumpriam os critérios de inclusão, 40 (18,3%) e 178 (81,7%) foram diagnosticados como portadores de HP associada à DVE (HP-DVE) e HAP, respectivamente. O grupo HP-DVE tinha idade significativamente mais avançada que aqueles com HAP (p < 0,0001). CONCLUSÕES: A diferença proporcional entre os grupos HAP e HP-DVE foi bastante significativa, considerando a inexistência de sinais ecocardiográficos sugestivos de DVE importante como parte da investigação que antecedeu ...


Assuntos
Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Cateterismo Cardíaco , Hipertensão Pulmonar/diagnóstico , Disfunção Ventricular Esquerda/diagnóstico , Cateterismo Cardíaco/métodos , Embolia Pulmonar , Testes de Função Respiratória , Disfunção Ventricular Esquerda/complicações
12.
J Bras Pneumol ; 40(6): 609-16, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25610501

RESUMO

OBJECTIVE: To evaluate the role of right heart catheterization in the diagnosis of pulmonary arterial hypertension (PAH). METHODS: We evaluated clinical, functional, and hemodynamic data from all patients who underwent right heart catheterization because of diagnostic suspicion of PAH--in the absence of severe left ventricular dysfunction (LVD), significant changes in pulmonary function tests, and ventilation/perfusion lung scintigraphy findings consistent with chronic pulmonary thromboembolism--between 2008 and 2013 at our facility. RESULTS: During the study period, 384 patients underwent diagnostic cardiac catheterization at our facility. Pulmonary hypertension (PH) was confirmed in 302 patients (78.6%). The mean age of those patients was 48.7 years. The patients without PH showed better hemodynamic profiles and lower levels of B-type natriuretic peptide. Nevertheless, 13.8% of the patients without PH were categorized as New York Heart Association functional class III or IV. Of the 218 patients who met the inclusion criteria, 40 (18.3%) and 178 (81.7%) were diagnosed with PH associated with LVD (PH-LVD) and with PAH, respectively. The patients in the HP-LVD group were significantly older than were those in the PAH group (p < 0.0001). CONCLUSIONS: The proportional difference between the PAH and PH-LVD groups was quite significant, considering the absence of echocardiographic signs suggestive of severe LVD during the pre-catheterization investigation. Our results highlight the fundamental role of cardiac catheterization in the diagnosis of PAH, especially in older patients, in whom the prevalence of LVD that has gone undiagnosed by non-invasive tests is particularly relevant.


OBJETIVO: Avaliar o papel do cateterismo de câmaras cardíacas direitas no diagnóstico de hipertensão arterial pulmonar (HAP). MÉTODOS: Entre 2008 e 2013, foram avaliadas as características clínicas, funcionais e hemodinâmicas de todos os pacientes que realizaram cateterismo cardíaco direito por suspeita de HAP em nosso laboratório, depois de afastada a presença de disfunção ventricular esquerda (DVE) grave, de alterações significativas nos testes de função pulmonar ou de resultados de cintilografia pulmonar de inalação/perfusão compatíveis com tromboembolismo pulmonar crônico. RESULTADOS: Durante o período de estudo, 384 pacientes foram submetidos a cateterismo cardíaco diagnóstico. A hipertensão pulmonar (HP) foi confirmada em 302 pacientes (78,6%). A média de idade desses pacientes foi de 48,7 anos. Os pacientes sem HP apresentaram melhor perfil hemodinâmico e menores níveis de peptídio natriurético do tipo B que aqueles diagnosticados com HP. No entanto, 13,8% dos pacientes sem HP apresentavam-se em classe funcional III/IV do New York Heart Association. Dos 218 pacientes que cumpriam os critérios de inclusão, 40 (18,3%) e 178 (81,7%) foram diagnosticados como portadores de HP associada à DVE (HP-DVE) e HAP, respectivamente. O grupo HP-DVE tinha idade significativamente mais avançada que aqueles com HAP (p < 0,0001). CONCLUSÕES: A diferença proporcional entre os grupos HAP e HP-DVE foi bastante significativa, considerando a inexistência de sinais ecocardiográficos sugestivos de DVE importante como parte da investigação que antecedeu o cateterismo. Nossos resultados reforçam o papel fundamental do cateterismo cardíaco no diagnóstico da HAP, ainda mais em faixas etárias mais avançadas, nas quais a prevalência de DVE não diagnosticada através de exames não invasivos é particularmente importante.


Assuntos
Cateterismo Cardíaco , Hipertensão Pulmonar/diagnóstico , Disfunção Ventricular Esquerda/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Cateterismo Cardíaco/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Embolia Pulmonar , Testes de Função Respiratória , Disfunção Ventricular Esquerda/complicações , Adulto Jovem
13.
Einstein (Säo Paulo) ; 9(1)jan.-mar. 2011. tab
Artigo em Inglês, Português | LILACS | ID: lil-583364

RESUMO

Objective: To evaluate the effect on quality of life of elderly people enrolled in the Grupo de Assistência Multidisciplinar ao Idoso Ambulatorial (GAMIA) of the Geriatric Service of the Hospital das Clínicas of the Faculdade de Medicina of Universidade de São Paulo. Methods: In 83 elderly participants of group between 2000 and 2002 the quality of life was assessed by the World Health Organization Quality of Life (WHOQOL-bref) at the beginning and the end of the program. Functionality was assessed by the Katz and Lawton scales and socio-demographic data were obtained from medical charts. Results: Females predominated (79.5%) and overall mean age was 69.30 years. Data analysis showed a reduction in the physical domain of WHOQOL-bref (p = 0.014) and increased psychological health and environment domains (p = 0.029 and p = 0.007 respectively), detecting a trend of increase in social relationships and in general domains (p = 0.062 and p = 0.052 respectively). Conclusions: The clinical evaluation of elderly may have the predominant factor for the deterioration of their perception in the physical domain because of the detection of previously unknown diseases and determination of the use of new drugs. Improvement in psychological health and the environment can be related to psychological and social support that the elderly received from peers and professionals and the benefits of group activities, as well as the upward trend observed in the social relationships and general domains. Participation in a program to promote healthy aging was effective in improving the quality of life of the elderly.


Objetivo: Avaliar os efeitos na qualidade de vida de idosos matriculados no Grupo de Assistência Multidisciplinar ao Idoso Ambulatorial (GAMIA) do Serviço de Geriatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Métodos: Nos 83 idosos participantes do grupo entre 2000 e 2002, a qualidade de vida foi avaliada pelo World Health Organization Quality of Life (WHOQOL-bref) no início e no fim do programa. A funcionalidade foi avaliada pelas Escalas de Katz e Lawton e os dados sociodemográficos foram obtidos nos prontuários. Resultados: Houve predomínio do sexo feminino (79,5%) e a média geral de idade foi de 69,30 anos. A análise dos dados mostraram uma redução no domínio físico do WHOQOL-bref (p = 0,014) e a elevação dos domínios psicológico e meio ambiente (p = 0,029 e p = 0,007, respectivamente), detectando-se tendência de elevação nos domínios relações sociais e geral (p = 0,062 e p = 0,052, respectivamente). Conclusões: Como a avaliação clínica desses idosos revelou doenças desconhecidas previamente e determinou a utilização de novos medicamentos, a percepção que os idosos tinham, em relação à sua saúde, pode ter sido o fator preponderante para a piora no domínio físico. A melhora dos domínios psicológico e meio ambiente pode estar relacionada ao suporte psicológico e social que o idoso recebeu dos colegas e profissionais e dos benefícios das atividades em grupo, bem como às tendência de elevação observada nos domínios relações sociais e geral. A participação em um programa de promoção do envelhecimento saudável mostrou-se eficaz na melhora da qualidade de vida do idoso.


Assuntos
Humanos , Feminino , Idoso , Masculino , Envelhecimento , Qualidade de Vida , Inquéritos e Questionários
14.
Einstein (Sao Paulo) ; 9(1): 8-13, 2011 Mar.
Artigo em Inglês, Português | MEDLINE | ID: mdl-26760546

RESUMO

OBJECTIVE: To evaluate the effect on quality of life of elderly people enrolled in GAMIA - Multidisciplinary Care Group to Outpatient Elderly Subjects (Grupo de Assistência Multidisciplinar ao Idoso Ambulatorial) of the Geriatric Department, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo. METHODS: Between 2000 and 2002, 83 elderly participants of GAMIA were assessed by the World Health Organization Quality of Life scale (WHOQOL-bref) at the beginning and the end of the program. Functionality was assessed by Katz and Lawton scales and sociodemographic data were obtained from medical charts. RESULTS: Females predominated (79.5%) and overall mean age was 69.30 years. Data analysis showed a reduction in the physical domain of WHOQOL-bref (p = 0.014) and increased psychological health and environment domains (p = 0.029 and p = 0.007, respectively), detecting a trend of increase in social relationships and in general domains (p = 0.062 and p = 0.052, respectively). CONCLUSIONS: The clinical evaluation of the elderly detected previously unknown diseases and determination of the use of new drugs, which might have been the predominant factor for the deterioration of their perception in the physical domain. Improvement in psychological health and the environment can be related to psychological and social support that the elderly received from peers and professionals and the benefits of group activities, as well as the upward trend observed in social relationships and general domains. Participation in a program to promote healthy aging was effective in improving the quality of life of the elderly.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...